No Data
No Data
Express News | AC Immune SA : Jefferies Cuts Target Price to $7 From $8
US Penny Stocks Spotlight: AC Immune And Two Others To Consider
AC Immune Announces Key Executive Promotions to Strengthen R&D Leadership
AC Immune Announces Promising Safety Data for Down Syndrome Therapy
Express News | AC Immune SA - ACI-24.060 Safe and Well Tolerated in Down Syndrome Patients
AC Immune Reports Interim Safety Data From Phase 1b/2 ABATE Trial of ACI-24.060 in Down Syndrome